ATRX is an inclusion eligibility criterion in 1 clinical trial for WHO grade III glioma, of which 0 are open and 1 is closed. Of the trial that contains ATRX status and WHO grade III glioma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [3].

EGFR is an inclusion eligibility criterion in 1 clinical trial for WHO grade III glioma, of which 1 is open and 0 are closed. Of the trial that contains EGFR status and WHO grade III glioma as inclusion criteria, 1 is phase 2 (1 open) [3].

ERBB2 is an inclusion eligibility criterion in 1 clinical trial for WHO grade III glioma, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 status and WHO grade III glioma as inclusion criteria, 1 is phase 2 (1 open) [3].

IDH1 is an inclusion eligibility criterion in 2 clinical trials for WHO grade III glioma, of which 2 are open and 0 are closed. Of the trials that contain IDH1 status and WHO grade III glioma as inclusion criteria, 1 is phase 2 (1 open) and 1 is phase 3 (1 open) [3].

IDH2 is an inclusion eligibility criterion in 2 clinical trials for WHO grade III glioma, of which 2 are open and 0 are closed. Of the trials that contain IDH2 status and WHO grade III glioma as inclusion criteria, 1 is phase 2 (1 open) and 1 is phase 3 (1 open) [3].

PDGFA is an inclusion eligibility criterion in 1 clinical trial for WHO grade III glioma, of which 1 is open and 0 are closed. Of the trial that contains PDGFA status and WHO grade III glioma as inclusion criteria, 1 is phase 2 (1 open) [3].

PDGFB is an inclusion eligibility criterion in 1 clinical trial for WHO grade III glioma, of which 1 is open and 0 are closed. Of the trial that contains PDGFB status and WHO grade III glioma as inclusion criteria, 1 is phase 2 (1 open) [3].

PDGFRA is an inclusion eligibility criterion in 1 clinical trial for WHO grade III glioma, of which 1 is open and 0 are closed. Of the trial that contains PDGFRA status and WHO grade III glioma as inclusion criteria, 1 is phase 2 (1 open) [3].

PDGFRB is an inclusion eligibility criterion in 1 clinical trial for WHO grade III glioma, of which 1 is open and 0 are closed. Of the trial that contains PDGFRB status and WHO grade III glioma as inclusion criteria, 1 is phase 2 (1 open) [3].

TP53 is an inclusion eligibility criterion in 1 clinical trial for WHO grade III glioma, of which 0 are open and 1 is closed. Of the trial that contains TP53 status and WHO grade III glioma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [3].